Entity

Time filter

Source Type

Lakewood, CO, United States

Gambro is a global medical technology companythat manufactures products for Dialysis treatment.The company is a global leader in developing, manufacturing andsupplying products and therapies for Kidneyand Liver Dialysis, Myeloma Kidney Therapy, and otherextracorporeal therapies for Chronic and Acute patients.Gambro was founded in Lund, Sweden in 1964 by HolgerCrafoord and has approx. 8,000 employees, productionfacilities in 9 countries, and sales in more than100 countries. In September 2013, Baxter Intl. completed its acquisition of Gambro. Wikipedia.


The present invention concerns an anticoagulation fluid comprising 10-40 m M citrate and 0.1-4 m M phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in the dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit.


The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 10-40 mM citrate, and 0.1-2.0 mM phosphate; and the at least one treatment fluid comprises 0-5 mM total calcium, 0-8 mM citrate, and 0.1-2.0 mM phosphate; with provisos that the at least one treatment fluid comprises citrate when total calcium concentration is 0 mM; and the at least one treatment fluid comprises calcium when the citrate concentration is 0 mM. The present invention further concerns a system for regional citrate anticoagulation in an extracorporeal blood circuit.


The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.


The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and 10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.


A monitoring device is arranged to receive a time-dependent measurement signal from a pressure sensor in a fluid containing system, which is associated with a first pulse generator and a second pulse generator. The pressure sensor is arranged in the fluid containing system to detect a first pulse originating from the first pulse generator and a second pulse originating from the second pulse generator. The monitoring device is configured to process the measurement signal to remove the first pulse. In this process, the monitoring device receives the measurement signal, obtains a first pulse profile which is a predicted temporal signal profile of the first pulse, and filters the measurement signal in the time-domain, using the first pulse profile, to essentially eliminate the first pulse while retaining the second pulse. The fluid containing system may include an extracorporeal blood flow circuit and a blood circuit of a human patient.

Discover hidden collaborations